A Randomized placebo clinical study and life style interventionon Mesha Shringyadi Gugglu in Medovridhhi

A RAndomiZed Placebo controlled Clinical Study on Mesha Shringyadi Gugglu And life style intervntion in the management of Medo Vridhhi( Hypertryglyceridemia)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2016/03/006709

Enrollment

Registered

2016-03-04

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patient with hypertryglyceridemia

Interventions

Intervention1: Mesha Shringyadi Guggulu: Form ofCapsule Dose in 2cap each 500mg) TDS Mode of administration Oral Time of administration Before breakfast, lunch and dinner Anupana Luke warm water Dur

Eligibility

Inclusion criteria

Inclusion criteria: S.cholesterol >200mg/dl or/and S.Triglyceride >150mg/dl or/and S.L.D.L >130mg/dl or /and S.H.D.L

Exclusion criteria

Exclusion criteria: Age below 25 and above 60 years Patients suffering from type 1 dm and uncotrolled dm patients having uncontrolled hypertention past history of MI unstabe angina renal disese liver disease

Design outcomes

Primary

Measure	Time frame
to show changes in lipid proofile mainly S triglyceride levelTimepoint: to show changes in lipid proofile mainly S triglyceride level	—

Secondary

Measure	Time frame
â?¢ By providing better effect on hypertriglyceridemia,drug may also reduce the risk of insuline resistance diabetes, metabolic syndrome, pancreatitis & IHD.Timepoint: Cange in lipid profile	—

Countries

India

Contacts

Public ContactBhabatosh Debbarma

IPGT and RA GAU JAmnagar

mandipgoyal22@gmail.com9427572306

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026